.png)
Onco-Summaries: Daily Oncology Updates at a Glance
- Oncofocus Team
- 4 days ago
- 1 min read
23/03/2026
AstraZeneca & Daiichi Sankyo's ENHERTU received approval in Japan for HER2+ solid cancers (Ref)
Japan’s Ministry of Health, Labour and Welfare (MHLW) granted approval to AstraZeneca & Daiichi Sankyo's ENHERTU® (trastuzumab deruxtecan) for the treatment of adult patients with HER2+, advanced or recurrent solid cancers refractory or intolerant to standard treatments.
The approval is based on results from four Phase 2 trials, including HERALD, DESTINYPanTumor02, DESTINY-CRC02 and DESTINY-Lung01
Comments